Gut Microbiome Testing in China: What the Results Can and Cannot Tell You
- MedBridgeNZ
- 5 days ago
- 11 min read
A gut microbiome test in China may be available as a stand-alone service or as an optional addition to a wider health-screening visit. The test analyses microbial DNA in a submitted stool sample and may describe which microorganisms were detected, their relative abundance and selected diversity measures.
The important question is not simply whether the test is available. It is whether the method, report and follow-up arrangements can answer the question you have in mind.
Key takeaway: A commercial microbiome report can describe features of one stool sample at one point in time. It cannot, by itself, diagnose a digestive condition or prescribe an individual diet, probiotic, supplement or treatment.
Quick Answer: What Is a Gut Microbiome Test?
A gut microbiome test is a laboratory analysis of microbial genetic material found in a stool sample. Depending on the provider and method, the report may include:
microorganisms detected in the sample;
their relative abundance;
measures of diversity;
comparisons with a provider’s reference database; and
in some reports, predicted microbial functions or wellness-related scores.
These results are descriptive. Their meaning depends on how the sample was collected, which sequencing method was used, how the data were processed and which population supplied the comparison data.
For someone arranging microbiome testing in Shanghai or elsewhere in China, practical details matter too: where the sample is collected, how it must be stored, whether the report is available in English and whether an appropriately qualified healthcare professional is available to explain it.
What Does a Commercial Microbiome Test Measure?
The final report is the product of a chain of steps—not a direct view of the entire digestive tract. Collection, preservation, DNA extraction, sequencing and bioinformatics all influence what appears on the page.
It starts with a stool sample
Most commercial tests require a small amount of stool to be placed in a laboratory-specified container or preservation tube. Instructions may cover the quantity required, contamination prevention, storage temperature and the deadline for returning the sample.
Those details are not merely packaging instructions. A 2024 Scientific Reports study found that preservation-buffer choice substantially affected the microbial-community and metabolomic profiles measured from stool samples. Travellers should therefore follow the receiving laboratory’s instructions rather than a generic collection guide.
Recent illness, diet and medicines may also affect microbial composition. Tell the facility about relevant antibiotics, proton-pump inhibitors, probiotics and other medicines before collection. Do not stop prescribed medication or deliberately alter your diet to change a result unless the referring clinician gives specific instructions.
16S vs. shotgun metagenomic sequencing: what changes in the report?
Two commonly discussed methods are 16S rRNA gene sequencing and shotgun metagenomic sequencing.
Think of 16S sequencing as reading a selected genetic barcode used mainly to profile bacterial groups. Shotgun metagenomics examines a much broader collection of DNA fragments from the sample. It can provide more detail, but the usefulness of that detail still depends on sequencing depth, reference databases and the laboratory’s analytical pipeline.
Method | What it analyses | What the report may provide |
16S rRNA gene sequencing | Selected regions of a bacterial marker gene | Broad bacterial community profiling, often at genus level |
Shotgun metagenomic sequencing | DNA fragments across the sample | Potentially broader taxonomic detail and functional-gene information, depending on depth and pipeline |
Shotgun sequencing is not automatically the better choice for every purpose. More data only helps when the workflow is validated, the report explains its limitations and the additional detail is relevant to the intended question.
Relative abundance is not a direct cell count
Relative abundance usually describes the proportion of analysed sequence data assigned to a microbial group compared with other groups in the same sample. It does not necessarily show the absolute number of microbial cells.
Reports may also include:
Alpha diversity, which describes variety within a sample, including richness and evenness; and
Beta diversity, which compares microbial patterns between samples or groups.
These metrics can help characterise a sample, but a higher diversity score is not automatically evidence of better health.
What Can the Result Potentially Describe?
A well-documented report can show which microbial features were detected and how the provider places them in context.
Microorganisms detected in the submitted sample
After sequencing, the laboratory compares processed DNA reads with one or more reference databases. The resulting list represents microbial DNA detected in that stool sample—not a complete inventory of every microorganism throughout the digestive tract.
Stool is a practical proxy for studying the gut microbiome, but different areas of the intestinal tract are not represented in exactly the same way.
Comparison with a reference database
Some reports compare a result with an average, percentile or category from a reference population. The comparison is more informative when the provider explains:
who is represented in the database;
how large and current it is;
whether age, geography, diet, medication and other relevant factors were considered; and
how labels such as “average”, “optimal” or “imbalanced” were calculated.
A score from one provider should not be assumed to mean the same thing as a similarly named score from another provider.
Associations found in research
Research has associated microbial patterns with numerous health conditions at group level. Such findings can guide research, but they do not show that a particular pattern caused an individual’s symptoms or will predict that person’s outcome.
When a report converts research findings into a disease-risk or wellness score, ask whether that exact use has demonstrated analytical validity, clinical validity and meaningful clinical benefit.
What Can a Microbiome Test Not Reliably Diagnose?
The 2025 international consensus statement on microbiome testing in clinical practice concluded that evidence was insufficient to recommend microbiome testing for widespread routine clinical use. The science is developing rapidly, but a commercial profile and a validated diagnostic test are not interchangeable.
There is no universal “healthy microbiome”
Gut microbiomes vary with age, geography, diet, medication, environment and health history. Current evidence does not support one ideal microbial composition or a strict universal range that defines health for everyone.
This is why a result that differs from a provider’s reference group should be read as a comparison with that particular dataset—not as proof that the person is unhealthy.
A dysbiosis score is not automatically a diagnosis
“Dysbiosis” is commonly used to describe a microbial pattern considered different from a reference group, but there is no single, universally accepted clinical definition. The international consensus did not identify a validated universal dysbiosis indicator and advised against using the Firmicutes-to-Bacteroidetes ratio as a stand-alone measure.
Before relying on an “out of range” score, ask how it was developed, whether it has been independently validated and whether it has a demonstrated role in the situation being assessed.
Disease-risk predictions require caution
Individual risk prediction requires more than an association in a research cohort. It needs suitable sensitivity, specificity, reproducibility and prospective validation for the intended population and purpose.
A gut microbiome report should not be used to confirm or exclude conditions such as irritable bowel syndrome, inflammatory bowel disease, infection, cancer or food intolerance.
Food and probiotic suggestions are not prescriptions
Some reports generate food, probiotic or supplement suggestions. The 2025 consensus discouraged therapeutic advice based on a microbiome profile alone. Any proposed change should account for the person’s symptoms, nutrition, medicines, diagnoses and other investigations.
The main risks of overinterpreting a report are false reassurance, unnecessary anxiety, restrictive diets, inappropriate supplement use and delay in seeking standard medical assessment for persistent or concerning symptoms.
Why Can Different Microbiome Tests Produce Different Results?
Similar material sent to two services may produce reports that do not fully agree. Differences can enter before sequencing and continue through the final scoring system.
Collection and storage: The sampled area, kit, preservative, temperature, transport time and freeze-thaw history can affect the DNA recovered.
Laboratory workflow: DNA-extraction methods, 16S target regions, primers, sequencing depth, contamination controls and quality thresholds vary.
Bioinformatics: Providers may use different software, database versions, taxonomic rules, normalisation methods and thresholds for low-abundance findings.
Reference populations: A score depends on the people and samples used to build the comparison dataset.
Timing and personal factors: Diet, illness, antibiotics and other medicines can change the microbiome within the same person over time.
In a 2026 Communications Biology study, researchers submitted standardised NIST-developed human faecal material to seven direct-to-consumer services. They found major discrepancies within and between providers; provider variation was on the same scale as biological variation between donors. This does not mean every service or hospital laboratory performs poorly. It shows why method disclosure, validation, quality control and reproducibility matter.
How Is Microbiome Profiling Different From Clinical Stool Testing?
Both may begin with a stool sample, but they are designed to answer different questions.
Decision question | General microbiome profile | Clinical stool test |
Primary purpose | Describe community composition and selected diversity measures | Investigate a defined clinical question |
Examples of methods | 16S or shotgun sequencing with bioinformatics | Culture, antigen testing, targeted nucleic-acid testing or immunoassay |
Typical outputs | Relative abundance, diversity and database comparisons | Detection of a specified pathogen, inflammatory marker, blood or another defined target |
Context | Often marketed for research interest or general wellness | Selected and interpreted in relation to symptoms, history and other findings |
For example, a clinician may order a targeted pathogen test when infection is suspected, faecal calprotectin when intestinal inflammation is being assessed, or a faecal immunochemical test for a specific screening or diagnostic pathway. These are not substitutes for general microbiome profiling, and a general profile is not a substitute for them.
Microbiome sequencing examines microbial DNA in a stool sample; it is different from tests that analyse a person’s own DNA, including whole exome sequencing and hereditary cancer panels covered in our guide to genetic testing during a health check in China.
Questions to Ask Before Purchasing a Test in China
If you are considering a stool microbiome test in China, ask specific questions rather than comparing only the number of organisms advertised.
1. What is the intended purpose?
Clarify whether the service is designed for general wellness profiling, research interest or a clinician-defined question. If symptoms are the reason for testing, ask whether a separate medical assessment or physician-ordered test is more appropriate.
2. Which laboratory and method are used?
Ask for the laboratory’s identity, relevant accreditation or quality system, sequencing method and intended use. Useful details may include the 16S target region, sequencing depth, quality controls, databases and evidence of reproducibility.
3. What exactly will appear in the report?
Confirm the expected taxonomic resolution, diversity measures, reference population, limitations and raw-data availability. A complex-looking report is not necessarily clinically validated.
4. Will the report and follow-up be available in English?
Do not assume that “English support” includes an English laboratory report or a clinician consultation. Confirm separately whether translation, administrative language assistance and qualified clinical interpretation are available.
5. What are the collection and turnaround requirements?
Ask which kit is required, where collection occurs, how the sample must be preserved and when it must reach the laboratory. Request a current turnaround estimate; timing may change with sample quality, repeat processing, holidays and workload.
6. How will the sample and data be handled?
Ask how long the sample and digital data will be retained, whether raw data can be downloaded, whether information may be used for research or transferred across borders, and how deletion requests are handled.
If microbiome profiling is only one part of a wider visit, review how a health screening in China is typically coordinated before asking whether the test can be added to the same itinerary.
Planning Microbiome Testing During a Health-Screening Visit in China
If you are trying to add microbiome testing to a short health-screening visit in Shanghai, the difficult part may not be collecting the sample. It is often confirming which facility currently offers the test, what method is used, whether the report is available in English and how follow-up questions will be handled.
Availability varies by hospital, laboratory relationship and current protocol. A microbiome profile may be a separate add-on rather than part of a standard or executive package. International visitors may also need to clarify registration, payment, report delivery and whether collection fits the itinerary.
MedBridgeNZ has previously coordinated an enquiry in which a Shanghai facility confirmed that microbiome profiling could be added to an existing family health-screening itinerary. That example does not establish permanent availability, a fixed price, a universal collection process or a guaranteed turnaround time. Each enquiry must be reconfirmed with the receiving facility.
How MedBridgeNZ can help with the administrative pathway
MedBridgeNZ can coordinate an enquiry with a receiving hospital or laboratory about current availability and booking requirements. A typical administrative pathway may include:
Clarifying the enquiry: We compile the traveller’s testing goal, preferred dates, wider screening plan, language needs and practical questions.
Confirming current requirements: We ask the receiving facility about the laboratory, method, collection kit, report format, turnaround estimate, data policy and options for qualified interpretation.
Coordinating the visit: Once the traveller has reviewed and accepted the facility’s requirements, we can assist with scheduling, registration and agreed logistics such as translation, bilingual accompaniment, transport or accommodation.
International visitors who need document translation, appointment coordination or on-the-ground logistics can review MedBridgeNZ’s medical coordination services.
Because availability and testing methods vary by facility, MedBridgeNZ’s partner hospital network should be treated as a starting point for a current enquiry rather than confirmation that every listed hospital offers microbiome testing.
Ask About Current Microbiome Testing Options
Planning microbiome testing as part of a health-screening visit in China? MedBridgeNZ can ask the receiving facility about current availability, sample requirements, report language, estimated turnaround time and follow-up arrangements.
Contact the MedBridgeNZ Patient Care Team to discuss the administrative enquiry and coordination process.
Frequently Asked Questions About Gut Microbiome Testing in China
Can a microbiome sample be collected during a health check in Shanghai?
It may be possible, but collection arrangements depend on the facility and its current laboratory protocol. Confirm whether the test is a separate add-on, which kit is required, where collection occurs and how quickly the sample must be submitted before finalising the appointment schedule.
How long does a gut microbiome report take?
There is no universal turnaround time. It depends on the method, laboratory workflow, sample quality and report format. Ask the receiving facility for its current estimate before making travel or follow-up plans.
Will the microbiome report be available in English?
Not necessarily. Confirm whether the original report will be issued in English, whether translation is available and whether any translated document is intended for administrative understanding or clinical use.
Do antibiotics or probiotics affect the result?
Antibiotics, probiotics and other medicines may affect microbial composition. Provide the laboratory or referring clinician with an accurate medication history and follow its preparation instructions. Do not stop or delay prescribed treatment for the purpose of testing unless the prescribing or referring clinician advises you to do so.
Will a doctor explain the result?
This varies by service. Ask whether an appropriately qualified healthcare professional is available to explain the findings and whether this costs extra. A translated report or wellness summary is not the same as clinical interpretation.
What happens if another result from my health check is abnormal?
The appropriate next step depends on the test, finding and wider medical context. If a report is described as abnormal, borderline or unclear, our guide explains what happens after abnormal health-screening results and what international visitors may need to coordinate next.
A Practical Decision, Not Just a Technology Purchase
A gut microbiome DNA test in China may offer a snapshot of microbial features in a submitted stool sample. Its practical value depends on the question, laboratory workflow, comparison database and access to appropriate interpretation.
Before booking, look beyond the number of organisms or scores displayed in a sample report. Confirm the method, collection process, report language, data policy, timing and follow-up route. For an international visitor, those details determine whether the test can fit safely and realistically into a wider health-screening itinerary.
Author: MedBridgeNZ Last Updated: August 2026
References
Porcari S, Mullish BH, Asnicar F, et al. International consensus statement on microbiome testing in clinical practice. The Lancet Gastroenterology & Hepatology. 2025;10(2):154–167. doi:10.1016/S2468-1253(24)00311-X. https://pubmed.ncbi.nlm.nih.gov/39647502/
Servetas SL, Gierz KS, Hoffmann D, et al. Evaluating the analytical performance of direct-to-consumer gut microbiome testing services. Communications Biology. 2026;9:269. doi:10.1038/s42003-025-09301-3. https://www.nature.com/articles/s42003-025-09301-3
Gemmell MR, Jayawardana T, Koentgen S, et al. Optimised human stool sample collection for multi-omic microbiota analysis. Scientific Reports. 2024;14:16816. doi:10.1038/s41598-024-67499-4. https://www.nature.com/articles/s41598-024-67499-4
Jovel J, Patterson J, Wang W, et al. Characterization of the gut microbiome using 16S or shotgun metagenomics. Frontiers in Microbiology. 2016;7:459. doi:10.3389/fmicb.2016.00459. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2016.00459/full
Disclaimer
MedBridgeNZ is an international medical concierge and logistics coordination provider. We do not provide medical advice, diagnosis or treatment. This article is for general informational purposes and should not replace advice from a primary physician, gastroenterologist or another appropriately qualified healthcare professional.
